Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of MV-CHIK Vaccine in Puerto Rico
NCT03101111Phase 2Completed
- Sponsor
- Themis Bioscience
- Start
- Aug 2017
- Primary completion
- Apr 2019
- Modality
- Viral Vectors, Live Attenuated Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of MV-CHIK in Chikungunya (CHIKV), sponsored by Themis Bioscience. Started Aug 2017; status: completed.
02
Drugs
MV-CHIK
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on NCT03101111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101111.